Verona Pharma Form 4: CFO Adds 229k Shares, Withholds 90k for Taxes
Rhea-AI Filing Summary
Verona Pharma plc (VRNA) – Form 4 insider filing
Chief Financial Officer Mark W. Hahn reported two equity transactions on 7 Jul 2025-8 Jul 2025.
- Equity award & conversion: 675,048 performance-based Restricted Share Units (RSUs) were granted after the Board confirmed that Q2 2025 performance metrics were met. On the same day 229,512 Ordinary Shares (≈28,689 ADSs) were issued on RSU conversion at a cost basis of $0.
- Tax withholding: 90,320 Ordinary Shares (≈11,290 ADSs) were automatically withheld at an effective price of $11.4413 to satisfy tax obligations; no open-market sale occurred.
- Post-transaction ownership: Hahn now holds 12,418,184 Ordinary Shares (≈1.55 million ADSs), all in direct ownership.
Because the RSUs vested only after Q2 targets were achieved, the filing signals that internal performance hurdles were met, a modestly positive data-point for investors. The net share movement (≈+139,000 Ordinary Shares) increases the CFO’s equity exposure, aligning his incentives with shareholders.
Positive
- Q2 2025 performance metrics achieved, triggering 675,048 RSUs and signaling internal execution progress
Negative
- None.
Insights
TL;DR: Routine insider award; Q2 targets hit, modestly positive, minimal market impact.
The grant and partial vesting of 675 k RSUs reflects the company’s achievement of Q2 2025 benchmarks, supporting the operational narrative ahead of earnings. Although 90 k shares were withheld for taxes, no discretionary sale took place, indicating confidence rather than profit-taking. The CFO’s total stake—about 1.55 million ADSs—remains substantial, reinforcing alignment with shareholders. From a trading-flow perspective the net share change is immaterial to float, so immediate price impact should be limited. Overall, the filing is neutral-to-slightly positive for sentiment.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Ordinary Shares | 90,320 | $11.4413 | $1.03M |
| Grant/Award | Restricted Share Units | 675,048 | $0.00 | -- |
| Exercise | Restricted Share Units | 229,512 | $0.00 | -- |
| Exercise | Ordinary Shares | 229,512 | $0.00 | -- |
Footnotes (1)
- Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units. The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on July 3, 2025 divided by eight (8). Consists of (i) 2,450,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 306,250 ADSs); and (ii) 9,968,184 Ordinary Shares underlying 1,246,023 ADSs. Represents an award of performance-based Restricted Share Units ("RSUs") covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. The RSUs were earned upon the determination by the Board of Directors of the Issuer (the "Determination Date") that certain performance metrics related to Q2 2025 had been achieved. The RSUs vested as to 34% of the total shares on the Determination Date, and vest as to the remainder of the shares in equal quarterly installments over a two year period on each of November 1, February 1, May 1 and August 1, subject to the Reporting Person's continued service to the Issuer on each vesting date.
